

The impact of a multidisciplinary, information technology supported program on blood pressure control in primary care

Submission date 29/06/2004	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 22/07/2004	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 01/02/2019	Condition category Circulatory System	☐ Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Stéphane Rinfret

Contact details

University of Montreal
Cardiology and Outcomes Research
Centre Hospitalier de l'Université de Montréal (Notre-Dame Hospital)
1560 Sherbrooke East
Montréal, QC
Canada
H2L 4M1
+1 514 890 8232
s.rinfret@umontreal.ca

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00374829

Protocol serial number

DCT 67995

Study information

Scientific Title

The impact of a multidisciplinary information technology-supported program on blood pressure control in primary care.

Study objectives

It is hypothesised that blood pressure control will be improved in patients receiving the program by increasing compliance with pharmacotherapy, the use of higher doses of anti-hypertensive agents and the use of more anti-hypertensive agents when appropriate, without adversely impacting quality of life.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the local ethics committee (Cité de la Santé de Laval Comité d'éthique et de la recherche) in November 2003.

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hypertension

Interventions

Intervention:

We have developed an Information Technology (IT)-based system to help empower patients to be responsible for monitoring their Blood Pressure (BP) and compliance and to facilitate communication with healthcare providers. The IT-based system links with actual pharmacy prescription refill and renewal data. Using these data as well as responses to questions on compliance and BP control that patients provide, the system:

- a. offers patients counselling and telephone reminders
- b. generates prescription refill and renewal reminder calls
- c. monitors patient recorded BP

The system generates monthly reports to the treating physician and pharmacist on compliance and blood pressure control, a retroaction that we expect will guide therapy. The system also links patients with a nurse if BP is inadequately controlled and/or if patients are non-compliant. These nurses can then provide appropriate counselling to patients and refer the patients to their physician or pharmacist as appropriate.

Control:

The control group will receive standard care with no access to the IT-based system and multidisciplinary approach.

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

The primary objective of this study is to evaluate the impact of a multidisciplinary, information-technology supported hypertension management program on the mean change in 24-hour systolic and diastolic BP levels measured using Ambulatory Blood Pressure Monitoring (ABPM) compared to usual care.

Key secondary outcome(s)

1. To assess the likely mechanisms that account for the results for the primary objective by measuring refill compliance and the number and dosage of anti-hypertensive agents assessed through pharmacy prescription data records over the 12-month study period as well as the number and nature of interventions by pharmacists, nurses and physicians
2. To assess the effect of the program on mean daytime and nocturnal BP, office BP measured, the proportion of subjects who achieve target office BP
3. To assess the impact of the program on patients perceived health related quality of life
4. To assess the impact of the program on the incidence of adverse cardiovascular events, including hospitalisation for uncontrolled hypertension, new onset angina, myocardial infarction, hospitalisation for unstable angina, hospitalisation for congestive heart failure, hospitalisation for stroke, hospitalisation for other vascular event, and cardiovascular death
5. To evaluate the potential economic benefits of the intervention, from a third-party payers perspective

Completion date

01/02/2008

Eligibility**Key inclusion criteria**

1. Male and female uncontrolled hypertensive subjects
2. 18 years of age or more

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

1. Having a life-threatening disease
2. Chronic atrial fibrillation
3. Unable to use an ordinary telephone
4. Pregnant at the initial visit
5. Participating in another clinical trial
6. Living with another subject that is currently participating in the study

Date of first enrolment

01/05/2004

Date of final enrolment

01/02/2008

Locations**Countries of recruitment**

Canada

Study participating centre

University of Montreal

Montréal, QC

Canada

H2L 4M1

Sponsor information**Organisation**

Canadian Institutes of Health Research (CIHR) (Canada)

ROR

<https://ror.org/01gavpb45>

Funder(s)**Funder type**

Research organisation

Funder Name

Canadian Institutes of Health Research (CIHR) (Canada) - <http://www.cihr-irsc.gc.ca> (ref: DCT 67995)

Funder Name

Pfizer Canada Inc. (Canada)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2009	01/02/2019	Yes	No